Clinical Trial

A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will assess the adverse events, tolerability, and how bretisilocin intramuscular (IM) Injection moves through the body of healthy adult Japanese, Han Chinese, and Non-Asian volunteers participants.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-25
Trial Details
NCT Number NCT07604558
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 26 participants
Start Date 2026-05-26
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-24